Financhill
Sell
45

ANIP Quote, Financials, Valuation and Earnings

Last price:
$68.12
Seasonality move :
-4.1%
Day range:
$65.96 - $68.39
52-week range:
$52.50 - $77.00
Dividend yield:
0%
P/E ratio:
55.43x
P/S ratio:
1.98x
P/B ratio:
3.52x
Volume:
565.9K
Avg. volume:
278.6K
1-year change:
8.03%
Market cap:
$1.5B
Revenue:
$614.4M
EPS (TTM):
-$1.27

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ANIP
ANI Pharmaceuticals
$187.3M $1.39 35.6% 68.6% $81.57
AGEN
Agenus
$49.7M $1.35 5.11% -71.03% $11.50
CNMD
Conmed
$338.4M $1.12 1.9% 16.99% $66.60
NVAX
Novavax
$149.2M -$0.11 -64.49% -82.16% $13.43
STE
Steris PLC
$1.4B $2.27 6.5% 55.14% $264.88
VTRS
Viatris
$3.5B $0.56 -8.99% 446.59% $11.3875
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ANIP
ANI Pharmaceuticals
$68.12 $81.57 $1.5B 55.43x $0.00 0% 1.98x
AGEN
Agenus
$6.72 $11.50 $184.2M -- $0.00 0% 1.13x
CNMD
Conmed
$49.25 $66.60 $1.5B 12.96x $0.20 1.62% 1.17x
NVAX
Novavax
$6.96 $13.43 $1.1B 2.63x $0.00 0% 0.95x
STE
Steris PLC
$227.62 $264.88 $22.4B 36.71x $0.57 1% 4.13x
VTRS
Viatris
$9.0800 $11.3875 $10.7B -- $0.12 5.29% 0.76x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ANIP
ANI Pharmaceuticals
58.41% -0.735 42.22% 1.86x
AGEN
Agenus
-10.89% 3.671 56.5% 0.09x
CNMD
Conmed
47.71% 1.431 47.76% 0.91x
NVAX
Novavax
180.06% 1.446 16.39% 1.84x
STE
Steris PLC
23.64% 0.478 9.17% 1.19x
VTRS
Viatris
47.53% 1.302 137.27% 0.77x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ANIP
ANI Pharmaceuticals
$124.1M $14.1M -2.24% -4.66% 12.92% $15.1M
AGEN
Agenus
$2.4M -$13.3M -- -- -56.41% -$25.6M
CNMD
Conmed
$177.8M $16M 6.38% 12.88% 4.97% $37.8M
NVAX
Novavax
$612.2M $515.5M -- -- 83.91% -$187.1M
STE
Steris PLC
$641.2M $279.6M 6.94% 9.5% 14.48% $189.9M
VTRS
Viatris
$1.2B -$8.9M -10.98% -20.24% -91.62% $459.1M

ANI Pharmaceuticals vs. Competitors

  • Which has Higher Returns ANIP or AGEN?

    Agenus has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of -104.99%. ANI Pharmaceuticals's return on equity of -4.66% beat Agenus's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ANIP
    ANI Pharmaceuticals
    62.95% $0.69 $1.1B
    AGEN
    Agenus
    10% -$20.60 -$288.8M
  • What do Analysts Say About ANIP or AGEN?

    ANI Pharmaceuticals has a consensus price target of $81.57, signalling upside risk potential of 22.48%. On the other hand Agenus has an analysts' consensus of $11.50 which suggests that it could grow by 71.13%. Given that Agenus has higher upside potential than ANI Pharmaceuticals, analysts believe Agenus is more attractive than ANI Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ANIP
    ANI Pharmaceuticals
    3 1 0
    AGEN
    Agenus
    1 3 0
  • Is ANIP or AGEN More Risky?

    ANI Pharmaceuticals has a beta of 0.568, which suggesting that the stock is 43.195% less volatile than S&P 500. In comparison Agenus has a beta of 1.511, suggesting its more volatile than the S&P 500 by 51.137%.

  • Which is a Better Dividend Stock ANIP or AGEN?

    ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Agenus pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ANIP or AGEN?

    ANI Pharmaceuticals quarterly revenues are $197.1M, which are larger than Agenus quarterly revenues of $24.1M. ANI Pharmaceuticals's net income of $15.7M is higher than Agenus's net income of -$25.3M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Agenus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.98x versus 1.13x for Agenus. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ANIP
    ANI Pharmaceuticals
    1.98x 55.43x $197.1M $15.7M
    AGEN
    Agenus
    1.13x -- $24.1M -$25.3M
  • Which has Higher Returns ANIP or CNMD?

    Conmed has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of 1.88%. ANI Pharmaceuticals's return on equity of -4.66% beat Conmed's return on equity of 12.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    ANIP
    ANI Pharmaceuticals
    62.95% $0.69 $1.1B
    CNMD
    Conmed
    55.33% $0.19 $1.9B
  • What do Analysts Say About ANIP or CNMD?

    ANI Pharmaceuticals has a consensus price target of $81.57, signalling upside risk potential of 22.48%. On the other hand Conmed has an analysts' consensus of $66.60 which suggests that it could grow by 35.23%. Given that Conmed has higher upside potential than ANI Pharmaceuticals, analysts believe Conmed is more attractive than ANI Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ANIP
    ANI Pharmaceuticals
    3 1 0
    CNMD
    Conmed
    0 5 0
  • Is ANIP or CNMD More Risky?

    ANI Pharmaceuticals has a beta of 0.568, which suggesting that the stock is 43.195% less volatile than S&P 500. In comparison Conmed has a beta of 1.202, suggesting its more volatile than the S&P 500 by 20.161%.

  • Which is a Better Dividend Stock ANIP or CNMD?

    ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Conmed offers a yield of 1.62% to investors and pays a quarterly dividend of $0.20 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Conmed pays out 18.62% of its earnings as a dividend. Conmed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ANIP or CNMD?

    ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Conmed quarterly revenues of $321.3M. ANI Pharmaceuticals's net income of $15.7M is higher than Conmed's net income of $6M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Conmed's PE ratio is 12.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.98x versus 1.17x for Conmed. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ANIP
    ANI Pharmaceuticals
    1.98x 55.43x $197.1M $15.7M
    CNMD
    Conmed
    1.17x 12.96x $321.3M $6M
  • Which has Higher Returns ANIP or NVAX?

    Novavax has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of 82.81%. ANI Pharmaceuticals's return on equity of -4.66% beat Novavax's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ANIP
    ANI Pharmaceuticals
    62.95% $0.69 $1.1B
    NVAX
    Novavax
    97.75% $2.93 $94.5M
  • What do Analysts Say About ANIP or NVAX?

    ANI Pharmaceuticals has a consensus price target of $81.57, signalling upside risk potential of 22.48%. On the other hand Novavax has an analysts' consensus of $13.43 which suggests that it could grow by 92.94%. Given that Novavax has higher upside potential than ANI Pharmaceuticals, analysts believe Novavax is more attractive than ANI Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ANIP
    ANI Pharmaceuticals
    3 1 0
    NVAX
    Novavax
    3 2 1
  • Is ANIP or NVAX More Risky?

    ANI Pharmaceuticals has a beta of 0.568, which suggesting that the stock is 43.195% less volatile than S&P 500. In comparison Novavax has a beta of 2.691, suggesting its more volatile than the S&P 500 by 169.079%.

  • Which is a Better Dividend Stock ANIP or NVAX?

    ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Novavax pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ANIP or NVAX?

    ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Novavax quarterly revenues of $626.3M. ANI Pharmaceuticals's net income of $15.7M is lower than Novavax's net income of $518.6M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Novavax's PE ratio is 2.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.98x versus 0.95x for Novavax. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ANIP
    ANI Pharmaceuticals
    1.98x 55.43x $197.1M $15.7M
    NVAX
    Novavax
    0.95x 2.63x $626.3M $518.6M
  • Which has Higher Returns ANIP or STE?

    Steris PLC has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of 9.84%. ANI Pharmaceuticals's return on equity of -4.66% beat Steris PLC's return on equity of 9.5%.

    Company Gross Margin Earnings Per Share Invested Capital
    ANIP
    ANI Pharmaceuticals
    62.95% $0.69 $1.1B
    STE
    Steris PLC
    43.31% $1.48 $8.7B
  • What do Analysts Say About ANIP or STE?

    ANI Pharmaceuticals has a consensus price target of $81.57, signalling upside risk potential of 22.48%. On the other hand Steris PLC has an analysts' consensus of $264.88 which suggests that it could grow by 16.37%. Given that ANI Pharmaceuticals has higher upside potential than Steris PLC, analysts believe ANI Pharmaceuticals is more attractive than Steris PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    ANIP
    ANI Pharmaceuticals
    3 1 0
    STE
    Steris PLC
    3 3 0
  • Is ANIP or STE More Risky?

    ANI Pharmaceuticals has a beta of 0.568, which suggesting that the stock is 43.195% less volatile than S&P 500. In comparison Steris PLC has a beta of 0.923, suggesting its less volatile than the S&P 500 by 7.704%.

  • Which is a Better Dividend Stock ANIP or STE?

    ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 1% to investors and pays a quarterly dividend of $0.57 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Steris PLC pays out 35.77% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ANIP or STE?

    ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Steris PLC quarterly revenues of $1.5B. ANI Pharmaceuticals's net income of $15.7M is lower than Steris PLC's net income of $145.7M. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Steris PLC's PE ratio is 36.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.98x versus 4.13x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ANIP
    ANI Pharmaceuticals
    1.98x 55.43x $197.1M $15.7M
    STE
    Steris PLC
    4.13x 36.71x $1.5B $145.7M
  • Which has Higher Returns ANIP or VTRS?

    Viatris has a net margin of 7.96% compared to ANI Pharmaceuticals's net margin of -93.48%. ANI Pharmaceuticals's return on equity of -4.66% beat Viatris's return on equity of -20.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    ANIP
    ANI Pharmaceuticals
    62.95% $0.69 $1.1B
    VTRS
    Viatris
    35.68% -$2.55 $29.8B
  • What do Analysts Say About ANIP or VTRS?

    ANI Pharmaceuticals has a consensus price target of $81.57, signalling upside risk potential of 22.48%. On the other hand Viatris has an analysts' consensus of $11.3875 which suggests that it could grow by 25.41%. Given that Viatris has higher upside potential than ANI Pharmaceuticals, analysts believe Viatris is more attractive than ANI Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ANIP
    ANI Pharmaceuticals
    3 1 0
    VTRS
    Viatris
    2 6 0
  • Is ANIP or VTRS More Risky?

    ANI Pharmaceuticals has a beta of 0.568, which suggesting that the stock is 43.195% less volatile than S&P 500. In comparison Viatris has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.435%.

  • Which is a Better Dividend Stock ANIP or VTRS?

    ANI Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viatris offers a yield of 5.29% to investors and pays a quarterly dividend of $0.12 per share. ANI Pharmaceuticals pays -8.77% of its earnings as a dividend. Viatris pays out -90.63% of its earnings as a dividend.

  • Which has Better Financial Ratios ANIP or VTRS?

    ANI Pharmaceuticals quarterly revenues are $197.1M, which are smaller than Viatris quarterly revenues of $3.3B. ANI Pharmaceuticals's net income of $15.7M is higher than Viatris's net income of -$3B. Notably, ANI Pharmaceuticals's price-to-earnings ratio is 55.43x while Viatris's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ANI Pharmaceuticals is 1.98x versus 0.76x for Viatris. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ANIP
    ANI Pharmaceuticals
    1.98x 55.43x $197.1M $15.7M
    VTRS
    Viatris
    0.76x -- $3.3B -$3B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
71
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
72
SBET alert for Jul 18

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
68
MCRI alert for Jul 18

Monarch Casino & Resort [MCRI] is up 19.81% over the past day.

Sell
41
NEGG alert for Jul 18

Newegg Commerce [NEGG] is up 17.85% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock